-
Clinics in Chest Medicine Mar 2015Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease, including... (Review)
Review
Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease, including disseminated, skin, and catheter-related disease, is more common in immunosuppressed than immunocompetent patients. Mycobacterium avium complex remains the most common cause of NTM infection, but rapid growers including Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum play an important role in skin and catheter-related infections. With the exception of antibiotic prophylaxis for AIDS patients, the prevention of NTM remains difficult. Management is complicated, involving restoration of immune function and removal of catheters in addition to treatment with species-specific antibiotics per current guidelines.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Humans; Immunocompromised Host; Immunosuppressive Agents; Lung Diseases; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria
PubMed: 25676522
DOI: 10.1016/j.ccm.2014.11.002 -
Microbiology Spectrum Jan 2017Rapidly growing mycobacteria (RGM) compose approximately one-half of the currently validated mycobacterial species and are divided into six major groups, including the... (Review)
Review
Rapidly growing mycobacteria (RGM) compose approximately one-half of the currently validated mycobacterial species and are divided into six major groups, including the Mycobacterium fortuitum group, M. chelonae/M. abscessus complex, M. smegmatis group, M. mucogenicum group, M. mageritense/M. wolinskyi, and the pigmented RGM. This review discusses each group and highlights the major types of infections associated with each group. Additionally, phenotypic and molecular laboratory identification methods, including gene sequencing, mass spectrometry, and the newly emerging whole-genome sequencing, are detailed, along with a discussion of the current antimicrobial susceptibility methods and patterns of the most common pathogenic species.
Topics: Bacteriological Techniques; Diagnostic Tests, Routine; Humans; Molecular Diagnostic Techniques; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria
PubMed: 28084211
DOI: 10.1128/microbiolspec.TNMI7-0027-2016 -
Frontiers in Microbiology 2018The genus contains 188 species including several major human pathogens as well as numerous other environmental species. We report here comprehensive phylogenomics and...
The genus contains 188 species including several major human pathogens as well as numerous other environmental species. We report here comprehensive phylogenomics and comparative genomic analyses on 150 genomes of species to understand their interrelationships. Phylogenetic trees were constructed for the 150 species based on 1941 core proteins for the genus , 136 core proteins for the phylum Actinobacteria and 8 other conserved proteins. Additionally, the overall genome similarity amongst the species was determined based on average amino acid identity of the conserved protein families. The results from these analyses consistently support the existence of five distinct monophyletic groups within the genus at the highest level, which are designated as the "," " "," "," and "" clades. Some of these clades have also been observed in earlier phylogenetic studies. Of these clades, the " clade forms the deepest branching lineage and does not form a monophyletic grouping with the "" clade of fast-growing species. In parallel, our comparative analyses of proteins from mycobacterial genomes have identified 172 molecular signatures in the form of conserved signature indels and conserved signature proteins, which are uniquely shared by either all species or by members of the five identified clades. The identified molecular signatures (or synapomorphies) provide strong independent evidence for the monophyly of the genus and the five described clades and they provide reliable means for the demarcation of these clades and for their diagnostics. Based on the results of our comprehensive phylogenomic analyses and numerous identified molecular signatures, which consistently and strongly support the division of known mycobacterial species into the five described clades, we propose here division of the genus into an emended genus encompassing the "" clade, which includes all of the major human pathogens, and four novel genera viz. gen. nov., gen. nov., gen. nov. and gen. nov. corresponding to the " " "," and " clades, respectively. With the division of mycobacterial species into these five distinct groups, attention can now be focused on unique genetic and molecular characteristics that differentiate members of these groups.
PubMed: 29497402
DOI: 10.3389/fmicb.2018.00067 -
European Journal of Case Reports in... 2021is a non-tuberculous mycobacterium that can cause skin infections in immunocompetent individuals. We report a case of skin infection by this agent in a woman with...
UNLABELLED
is a non-tuberculous mycobacterium that can cause skin infections in immunocompetent individuals. We report a case of skin infection by this agent in a woman with dyslipidaemia, that culminated in statin-induced rhabdomyolysis due to the combination of clarithromycin, ciprofloxacin and simvastatin.
LEARNING POINTS
Skin infection with is an increasing global problem among immunocompetent individuals.Statin-induced rhabdomyolysis is an important and avoidable end-result of drug-drug interaction.Inhibition of cytochrome P450 isoenzyme 3A4 and of organic anion transporting polypeptide 1B1 are two important examples of statin interference with metabolism, and clarithromycin can inhibit both.
PubMed: 34268273
DOI: 10.12890/2021_002661 -
Antimicrobial Agents and Chemotherapy Feb 2021Infections caused by nontuberculous mycobacteria (NTM) are increasing globally. complex (MAC) and complex are the most frequently encountered NTM, and oral treatment...
Infections caused by nontuberculous mycobacteria (NTM) are increasing globally. complex (MAC) and complex are the most frequently encountered NTM, and oral treatment options are extremely limited for these pathogens, especially for the complex. In this study, the potency of omadacycline, a new tetracycline derivative, was tested against 111 isolates of NTM. MIC testing was performed as recommended by the Clinical and Laboratory Standards Institute against 70 isolates of rapidly growing mycobacteria (RGM), of which >90% were tetracycline resistant. These included subsp. (20 isolates), subsp. (3), (15 isolates), (7 isolates), the group, including six doxycycline-resistant isolates (12 isolates), and the group, including four doxycycline-resistant isolates (10 isolates). Forty-one isolates of slowly growing mycobacteria (SGM), including 16 isolates of MAC, were also tested. Omadacycline was active against all RGM species, with MIC ranges of 0.004 to 0.25 and 0.06 to 1 μg/ml for 80% and 100% inhibition, respectively. For subsp. , MICs were 0.06 and 0.12 μg/ml with 80% and 100% inhibition, respectively. There was considerable trailing of the omadacycline endpoint with the RGM. MICs of tigecycline exhibited no trailing and were generally within 1 to 2 dilutions of the 100% inhibition omadacycline MICs. While there was no trailing observed in SGM, omadacycline MICs were higher (MIC range, 8 to >16 μg/ml; = 41), as previously noted with tigecycline. This study supports further research of omadacycline, including clinical trials, for the treatment of RGM infections, especially .
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Mycobacteriaceae; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tetracyclines
PubMed: 33288634
DOI: 10.1128/AAC.01947-20 -
Journal of Clinical Microbiology Nov 2019
PubMed: 31645415
DOI: 10.1128/JCM.01394-18 -
G3 (Bethesda, Md.) Aug 2022Mycobacterium abscessus is an emerging pathogen of concern in cystic fibrosis and immunocompromised patients and is considered one of the most drug-resistant...
Mycobacterium abscessus is an emerging pathogen of concern in cystic fibrosis and immunocompromised patients and is considered one of the most drug-resistant mycobacteria. The majority of clinical Mycobacterium abscessus isolates carry 1 or more prophages that are hypothesized to contribute to virulence and bacterial fitness. The prophage McProf was identified in the genome of the Bergey strain of Mycobacterium chelonae and is distinct from previously described prophages of Mycobacterium abscessus. The McProf genome increases intrinsic antibiotic resistance of Mycobacterium chelonae and drives expression of the intrinsic antibiotic resistance gene, whiB7, when superinfected by a second phage. The prevalence of McProf-like genomes was determined in sequenced mycobacterial genomes. Related prophage genomes were identified in the genomes of 25 clinical isolates of Mycobacterium abscessus and assigned to the novel cluster, MabR. They share less than 10% gene content with previously described prophages; however, they share features typical of prophages, including polymorphic toxin-immunity systems.
Topics: Anti-Bacterial Agents; Humans; Mycobacterium; Mycobacterium abscessus; Mycobacterium chelonae; Prophages
PubMed: 35894699
DOI: 10.1093/g3journal/jkac188